Craig A. Portell, MD

Rezazadeh, A., Szabo, A., Khurana, A., Inwards, D. J., Lunning, M. A., Bartlett, N. L., . . . Fenske, T. S. (2024). Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study. HAEMATOLOGICA, 109(5), 1439-1444. doi:10.3324/haematol.2023.283210

Filosto, S., Vardhanabhuti, S., Canales, M. A., Poire, X., Lekakis, L. J., de Vos, S., . . . Westin, J. R. (2024). Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7). BLOOD CANCER DISCOVERY, 5(1), 21-33. doi:10.1158/2643-3230.BCD-23-0112

Ayers, E., Canderan, G., Williams, M. E., Keshavarz, B., Portell, C. A., Wilson, J. M., & Woodfolk, J. A. (2023). In-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms. BLOOD CANCER JOURNAL, 13(1). doi:10.1038/s41408-023-00884-w

Jayappa, K. D., Tran, B., Gordon, V. L., Morris, C., Saha, S., Farrington, C. C., . . . Narla, G. (2023). PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis. JOURNAL OF CLINICAL INVESTIGATION, 133(13). doi:10.1172/JCI155938

Sawalha, Y., Goyal, S., Switchenko, J. M., Romancik, J. T., Kamdar, M., Greenwell, I. B., . . . Cohen, J. B. (2023). A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. BLOOD ADVANCES, 7(13), 2983-2993. doi:10.1182/bloodadvances.2022008916

Lantz, J., Portell, C. A., & Ayers, E. C. (2023). Central nervous system prophylaxis in diffuse large B-cell lymphoma: What does the evidence tell us?. BLOOD REVIEWS, 61. doi:10.1016/j.blre.2023.101101

Hess, B. T. T., Giri, A., Park, Y., Patel, K. K. K., Link, B. K. K., Nowakowski, G. S. S., . . . Castillo, J. J. J. (2023). Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study. AMERICAN JOURNAL OF HEMATOLOGY, 98(2), 300-308. doi:10.1002/ajh.26784

Cortese, M. J., Wei, W., Cerdena, S., Watkins, M. P., Olson, M., Jodon, G., . . . Hill, B. T. (2023). A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma. LEUKEMIA & LYMPHOMA, 64(1), 107-118. doi:10.1080/10428194.2022.2140281

Portell, C. A. (2022). CNS prophylaxis in DLBCL: first do no harm. BLOOD, 139(16), 2420-2421. doi:10.1182/blood.2022015432

Orellana-Noia, V. M., Reed, D. R., McCook, A. A., Sen, J. M., Barlow, C. M., Malecek, M. -K., . . . Portell, C. A. (2022). Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. BLOOD, 139(3), 413-423. doi:10.1182/blood.2021012888

Roeker, L. E., Eyre, T. A., Thompson, M. C., Lamanna, N., Coltoff, A. R., Davids, M. S., . . . Mato, A. R. (2021). COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. BLOOD, 138(18), 1768-+. doi:10.1182/blood.2021011841

Portell, C. A., Wages, N. A., Kahl, B. S., Budde, L. E., Chen, R. W., Cohen, J. B., . . . Williams, M. E. (2022). Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma. BLOOD ADVANCES, 6(5), 1490-1498. doi:10.1182/bloodadvances.2021005357

Orellana-Noia, V. M., Isaac, K., Malecek, M. -K., Bartlett, N. L., Voorhees, T. J., Grover, N. S., . . . Portell, C. A. (2021). Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. BLOOD ADVANCES, 5(18), 3623-3632. doi:10.1182/bloodadvances.2021004645

Opat, S., Tedeschi, A., Linton, K., McKay, P., Hu, B., Chan, H., . . . Trotman, J. (2021). The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. CLINICAL CANCER RESEARCH, 27(23), 6323-6332. doi:10.1158/1078-0432.CCR-21-1704

Jayappa, K. D., Gordon, V. L., Morris, C. G., Wilson, B., Shetty, B. D., Cios, K. J., . . . Weber, M. J. (2021). Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL. BLOOD ADVANCES, 5(17), 3497-3510. doi:10.1182/bloodadvances.2020003944

Alderuccio, J. P., Olszewski, A. J., Evens, A. M., Collins, G. P., Danilov, A. V., Bower, M., . . . Cwynarski, K. (2021). HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. BLOOD ADVANCES, 5(14), 2852-2862. doi:10.1182/bloodadvances.2021004458

Isaac, K. M., Portell, C. A., & Williams, M. E. (2021). Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management. CURRENT ONCOLOGY REPORTS, 23(9). doi:10.1007/s11912-021-01094-y

Zayac, A. S., Evens, A. M., Danilov, A., Smith, S. D., Jagadeesh, D., Leslie, L. A., . . . Olszewski, A. J. (2021). Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. HAEMATOLOGICA, 106(7), 1932-1942. doi:10.3324/haematol.2020.270876

Olszewski, A. J., Jakobsen, L. H., Collins, G. P., Cwynarski, K., Bachanova, V., Blum, K. A., . . . Evens, A. M. (2021). Burkitt Lymphoma International Prognostic Index. JOURNAL OF CLINICAL ONCOLOGY, 39(10), 1129-+. doi:10.1200/JCO.20.03288

Evens, A. M., Danilov, A., Jagadeesh, D., Sperling, A., Kim, S. -H., Vaca, R., . . . Alderuccio, J. P. (2021). Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. BLOOD, 137(3), 374-386. doi:10.1182/blood.2020006926

Mato, A. R., Roeker, L. E., Lamanna, N., Allan, J. N., Leslie, L., Pagel, J. M., . . . Eyre, T. A. (2020). Outcomes of COVID-19 in patients with CLL: a multicenter international experience. BLOOD, 136(10), 1134-1143. doi:10.1182/blood.2020006965

Mato, A. R., Roeker, L. E., Jacobs, R., Hill, B. T., Lamanna, N., Brander, D., . . . Eyre, T. A. (2020). Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. CLINICAL CANCER RESEARCH, 26(14), 3589-3596. doi:10.1158/1078-0432.CCR-19-3815

Krishnan, R., Ring, K., Williams, E., Portell, C., Jaffe, E. S., & Gru, A. A. (2020). An Enteropathy-like Indolent NK-Cell Proliferation Presenting in the Female Genital Tract. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 44(4), 561-565. doi:10.1097/PAS.0000000000001387

Ayers, E. C., Li, S., Medeiros, L. J., Bond, D. A., Maddocks, K. J., Torka, P., . . . Landsburg, D. J. (2020). Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. CANCER, 126(2), 293-303. doi:10.1002/cncr.32526

Reed, D. R., Hall, R. D., Gentzler, R. D., Volodin, L., Douvas, M. G., & Portell, C. A. (2019). Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 19(6), E247-E250. doi:10.1016/j.clml.2019.03.001

Hill, B. T., Nastoupil, L., Winter, A. M., Becnel, M. R., Cerhan, J. R., Habermann, T. M., . . . Kahl, B. S. (2019). Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 184(4), 524-535. doi:10.1111/bjh.15720

Davids, M. S., von Keudell, G., Portell, C. A., Cohen, J. B., Fisher, D. C., Foss, F., . . . Tam, C. S. (2018). Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 36(35), 3525-+. doi:10.1200/JCO.18.00359

Flinn, I. W., Hillmen, P., Montillo, M., Nagy, Z., Illes, A., Etienne, G., . . . Stilgenbauer, S. (2018). The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. BLOOD, 132(23), 2446-2455. doi:10.1182/blood-2018-05-850461

Mock, J., Kunk, P. R., Palkimas, S., Sen, J. M., Devitt, M., Horton, B., . . . Maitland, H. (2018). Risk of Major Bleeding with Ibrutinib. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 18(11), 755-761. doi:10.1016/j.clml.2018.07.287

Arora, P. C., & Portell, C. A. (2018). Novel therapies for relapsed/refractory mantle cell lymphoma. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 31(1), 105-113. doi:10.1016/j.beha.2017.10.010

Karlin, J., Peck, T., Prenshaw, K., Portell, C. A., & Kirzhner, M. (2017). Orbital mantle cell lymphoma presenting as myasthenia gravis. ORBIT-AN INTERNATIONAL JOURNAL ON ORBITAL DISORDERS AND FACIAL RECONSTRUCTIVE SURGERY, 36(6), 365-369. doi:10.1080/01676830.2017.1337202

Jayappa, K. D., Portell, C. A., Gordon, V. L., Capaldo, B. J., Bekiranov, S., Axelrod, M. J., . . . Weber, M. J. (2017). Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL (vol 14, pg 933, 2017). BLOOD ADVANCES, 1(19), 1537. doi:10.1182/bloodadvances.2017011148

Wages, N. A., Portell, C. A., Williams, M. E., Conaway, M. R., & Petroni, G. R. (2017). Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents. CLINICAL CANCER RESEARCH, 23(23), 7158-7164. doi:10.1158/1078-0432.CCR-17-1069

Jayappa, K. D., Portell, C. A., Gordon, V. L., Capaldo, B. J., Bekiranov, S., Axelrod, M. J., . . . Weber, M. J. (2017). Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. BLOOD ADVANCES, 1(14), 933-946. doi:10.1182/bloodadvances.2016004176

Martin, P., Maddocks, K., Leonard, J. P., Ruan, J., Goy, A., Wagner-Johnston, N., . . . Blum, K. A. (2016). Postibrutinib outcomes in patients with mantle cell lymphoma. BLOOD, 127(12), 1559-1563. doi:10.1182/blood-2015-10-673145

Foster, L. H., & Portell, C. A. (2015). The Role of Infectious Agents, Antibiotics, and Antiviral Therapy in the Treatment of Extranodal Marginal Zone Lymphoma and Other Low-Grade Lymphomas. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 16(6). doi:10.1007/s11864-015-0344-6

Wages, N. A., Conaway, M. R., Slingluff, C. L. J., Williams, M. E., Portell, C. A., Hwu, P., & Petroni, G. R. (2015). Recent developments in the implementation of novel designs for early-phase combination studies. ANNALS OF ONCOLOGY, 26(5), 1036-1037. doi:10.1093/annonc/mdv075

Portell, C. A., Aronow, M. E., Rybicki, L. A., Macklis, R., Singh, A. D., & Sweetenham, J. W. (2014). Clinical Characteristics of 95 Patients With Ocular Adnexal and Uveal Lymphoma: Treatment Outcomes in Extranodal Marginal Zone Subtype. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 14(3), 203-210. doi:10.1016/j.clml.2013.10.011

Aronow, M. E., Portell, C. A., Sweetenham, J. W., & Singh, A. D. (2014). Uveal Lymphoma: Clinical Features, Diagnostic Studies, Treatment Selection, and Outcomes. OPHTHALMOLOGY, 121(1), 334-341. doi:10.1016/j.ophtha.2013.09.004

Portell, C. A., & Advani, A. S. (2014). Novel targeted therapies in acute lymphoblastic leukemia. LEUKEMIA & LYMPHOMA, 55(4), 737-748. doi:10.3109/10428194.2013.823493

Bodo, J., Zhao, X., Sharma, A., Hill, B. T., Portell, C. A., Lannutti, B. J., . . . Hsi, E. D. (2013). The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways. BRITISH JOURNAL OF HAEMATOLOGY, 163(1), 72-80. doi:10.1111/bjh.12498

Aronow, M. E., Portell, C. A., Rybicki, L. A., Sweetenham, J. W., & Singh, A. D. (2013). Ocular Adnexal Lymphoma: Assessment of a Tumor-Node-Metastasis Staging System. OPHTHALMOLOGY, 120(9), 1915-1919. doi:10.1016/j.ophtha.2013.02.003

Portell, C. A., Wenzell, C. M., & Advani, A. S. (2013). Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 5, 5-11. doi:10.2147/CPAA.S42689

Portell, C. A., & Advani, A. S. (2012). Antibody Therapy for Acute Lymphoblastic Leukemia. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 7(2), 153-159. doi:10.1007/s11899-012-0120-7

Portell, C. A., & Sweetenham, J. W. (2012). Adult Lymphoblastic Lymphoma. CANCER JOURNAL, 18(5), 432-438. doi:10.1097/PPO.0b013e31826b1232

Portell, C. A., Sekeres, M. A., Rogers, H. J., & Tiu, R. V. (2012). De Novo polycythaemia vera arising 5 years following acute myeloid leukemia remission: suggestion of a chemotherapy resistant JAK2 clone. BRITISH JOURNAL OF HAEMATOLOGY, 157(2), 266-267. doi:10.1111/j.1365-2141.2011.08972.x